Karlheinz Peter MD, PhD, works as an interventional cardiologist at the Alfred Hospital and as Associate Director and Head of the Atherothrombosis and Vascular Biology Program at Baker IDI Heart and Diabetes Institute, Melbourne, Australia. He is Adjunct Professor of Medicine and Immunology at Monash University and Medical Science at RMIT and he is a NHMRC principal research fellow. He obtained his research and clinical training in at the Universities of Freiburg and Heidelberg in Germany and at Johns Hopkins Medical School and Scripps Research Institute in the US. His research is focused on the cellular mechanisms, prevention and novel therapeutic approaches in myocardial infarction, encompassing the role of platelets, coagulation and inflammation in atherosclerosis, as well as the mechanisms leading to the rupture of atherosclerotic plaques. Using recombinant antibody techno-logies he has developed novel biomarker and molecular imaging strategies using magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, ultrasound and fluorescence imaging as well as novel anti-inflammatory, anti-thrombotic and fibrinolytic approaches that are not associated with side effects such as increased bleeding risks.